NCT00811564

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 148 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects

Conditions

• Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution	1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
DRUG	latanoprost 0.005%	1 drop of study medication taken once daily

Timeline

• Start date: 2008-12-01
• Primary completion: 2010-01-01
• Completion: 2010-01-01
• First posted: 2008-12-19
• Last updated: 2011-09-21
• Results posted: 2011-09-21

Locations

1 site across 1 country: United States